Overview

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Status:
NOT_YET_RECRUITING

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity

Phase:

PHASE3

Details

Lead Sponsor:

Fujian Shengdi Pharmaceutical Co., Ltd.

Treatments:

semaglutide